Ipilimumab
Sign in to saveAlso known as MDX-010, MDX-101, MOAB-CTLA-4, MDX-CTLA-4
monoklonaler Antikörper zur Behandlung von Melanomen
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Antibody
- First approval
- 2011
- Admin. routes
- parenteral
- Indications
- carcinoma, melanoma, prostate carcinoma, metastatic melanoma
via ChEMBL · EBI
Research
7,201 papers- Improved survival with ipilimumab in patients with metastatic melanoma.The New England journal of medicine · 2010
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.The New England journal of medicine · 2019
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.The New England journal of medicine · 2017
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.The Lancet. Oncology · 2018
- The foundations of immune checkpoint blockade and the ipilimumab approval decennial.Nature reviews. Drug discovery · 2022
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 6 more facts
- route of administration
- intravenous infusion and defusion
- World Health Organisation international non-proprietary name
- ipilimumab
- medical condition treated
- skin cancer
- has characteristic
- biopharmaceutical
- subject has role
- monoclonal antibody
- physically interacts with
- cytotoxic T-lymphocyte associated protein 4
Sources (6)
via Wikidata · CC0
Article · Deutsch
Ipilimumab (MDX-010; Handelsname Yervoy) ist ein biotechnologisch hergestellter, vollständig humaner monoklonaler Antikörper, der in der Behandlung von Melanomen, Nierenzellkarzinomen, Mesotheliomen sowie bestimmten Formen von nicht-kleinzelligem Bronchialkarzinom oder metastasiertem Colonkarzinom eingesetzt wird. Die Wirkung richtet sich gegen das Protein CTLA-4.
Abstract from DBpedia / Wikipedia · CC BY-SA